This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
Additionally, Yescarta demonstrated a 2.5 fold increase in patients who were alive at two years without disease progression or need for additional cancer treatment versus SOC. ... Moreover, improvements in EFS with Yescarta were consistent across key
Yescarta (axicabtagene ciloleucel) reached $175m in relapsed/refractory large B-cell lymphoma and relapsed/refractory indolent follicular lymphoma in both the US and Europe.
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel). ... Meanwhile, Yescarta is used to treat follicular lymphoma and is also approved in the US for the
After a median follow-up of two years, Yescarta showed a 60.2% improvement in event-free survival (EFS) compared to SOC. ... Yescarta has been instrumental in transforming outcomes for patients with third-line LBCL.
Gilead was also bolstered by sales of its cell therapy products, which jumped by 36% to $191m in the first quarter, with Yescarta bringing in $160m and Tecartus bringing in $31m.
marginal zone lymphoma patients were enrolled and treated with Yescarta following two or more prior lines of therapy. ... Kite also recently revealed some positive data for Yescarta in the first-line setting for patients with high-risk large B-cell
More from news
Approximately 15 fully matching, plus 58 partially matching documents found.
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving
as Kymriah and Yescarta.
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...